Hormone replacement therapy: (2) Risks and benefis

Pharmaceutical Journal

Volumn 271, Issue 7274, 2003, Pages 646-648

  Tanna, Nuttan ^a,b  

^a EALING HOSPITAL NHS TRUST   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; PLACEBO;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DECISION MAKING; DRUG EXPOSURE; ENDOMETRIUM CANCER; FEMALE; GENERAL PRACTITIONER; HORMONE SUBSTITUTION; HUMAN; LIBIDO; MEDICAL RESEARCH; MENOPAUSE; OSTEOPOROSIS; OVARY CANCER; PATIENT COUNSELING; PHARMACIST; RISK BENEFIT ANALYSIS; STROKE; UROGENITAL TRACT DISEASE; VASOMOTOR DISORDER; VEIN THROMBOSIS;

EID: 0345255747     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. The heart and estrogen/progestin replacement study research group (HERS). Randomised trial of oestrogen plus progesterone is secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
2. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:49-57.
3. Writing group for the Women's Health Initiative (WHI) investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women. Principal results from the WHI randomised controlled trial. JAMA 2002;288:321-33.
4. Beral V for the Million Women study collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
5. Royal College of Physicians. Osteoporosis: clinical guidelines for prevention and treatment. Available at: www. rcplondon.ac.uk (accessed on 4 November 2003).
6. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy. Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
7. Beresford SA, Weiss N, Voigt L, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458-61.
8. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.